1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	World	_	_	NNP	_	_	_	_	_
3	Health	_	_	NNP	_	_	_	_	_
4	Organization	_	_	NNP	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	WHO	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	evidence	_	_	NN	_	_	_	_	_
9	reviews	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	published	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	International	_	_	NNP	_	_	_	_	_
15	Journal	_	_	NNP	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	Environmental	_	_	NNP	_	_	_	_	_
18	Research	_	_	NNP	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	Public	_	_	NNP	_	_	_	_	_
21	Health	_	_	NNP	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	have	_	_	VBP	_	_	_	_	_
24	revealed	_	_	VBN	_	_	_	_	_
25	sufficient	_	_	JJ	_	_	_	_	_
26	evidence	_	_	NN	_	_	_	_	_
27	that	_	_	IN	_	_	_	_	_
28	sources	_	_	NNS	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	transportation	_	_	NN	_	_	_	_	_
31	noise	_	_	NN	_	_	_	_	_
32	lead	_	_	VBP	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	serious	_	_	JJ	_	_	_	_	_
35	annoyance	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	sleep	_	_	NN	_	_	_	_	_
38	disturbance	_	_	NN	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	cardio-metabolic	_	_	JJ	_	_	_	_	_
42	disorders	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Less	_	_	RBR	_	_	_	_	_
2	convincing	_	_	JJ	_	_	_	_	_
3	evidence	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	no	_	_	DT	_	_	_	_	_
6	exposure-response	_	_	NN	_	_	_	_	_
7	information	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	provided	_	_	VBN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	mental	_	_	JJ	_	_	_	_	_
12	health	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Mental	_	_	JJ	_	_	_	_	_
2	health	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	perquisite	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	well-being	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	participation	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	social	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	economic	_	_	JJ	_	_	_	_	_
14	life	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	burden	_	_	NN	_	_	_	_	_
19	already	_	_	RB	_	_	_	_	_
20	amounting	_	_	VBG	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	about	_	_	RB	_	_	_	_	_
23	4	_	_	CD	_	_	_	_	_
24	%	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	gross	_	_	JJ	_	_	_	_	_
28	domestic	_	_	JJ	_	_	_	_	_
29	product	_	_	NN	_	_	_	_	_
30	across	_	_	IN	_	_	_	_	_
31	European	_	_	JJ	_	_	_	_	_
32	Union	_	_	NNP	_	_	_	_	_
33	countries	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Unlike	_	_	IN	_	_	_	_	_
2	other	_	_	JJ	_	_	_	_	_
3	chronic	_	_	JJ	_	_	_	_	_
4	diseases	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	mental	_	_	JJ	_	_	_	_	_
7	disorders	_	_	NNS	_	_	_	_	_
8	such	_	_	JJ	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	anxiety	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	depression	_	_	NN	_	_	_	_	_
13	show	_	_	VBP	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	early-life	_	_	JJ	_	_	_	_	_
16	onset	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	ranging	_	_	VBG	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	mild	_	_	JJ	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	time-limited	_	_	JJ	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	chronic	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	severe	_	_	JJ	_	_	_	_	_
27	impairments	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	feature	_	_	NN	_	_	_	_	_
3	makes	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	illness	_	_	NN	_	_	_	_	_
6	difficult	_	_	JJ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	identify	_	_	VB	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	therefore	_	_	RB	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	often	_	_	RB	_	_	_	_	_
16	poorly	_	_	RB	_	_	_	_	_
17	treated	_	_	VBN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	overlooked	_	_	VBN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	12-month	_	_	JJ	_	_	_	_	_
3	point	_	_	NN	_	_	_	_	_
4	prevalence	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	anxiety	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	depressive	_	_	JJ	_	_	_	_	_
9	disorders	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	Western	_	_	JJ	_	_	_	_	_
12	countries	_	_	NNS	_	_	_	_	_
13	sums	_	_	VBZ	_	_	_	_	_
14	up	_	_	RP	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	10	_	_	CD	_	_	_	_	_
17	%	_	_	NN	_	_	_	_	_
18	–	_	_	:	_	_	_	_	_
19	14	_	_	CD	_	_	_	_	_
20	%	_	_	NN	_	_	_	_	_
21	on	_	_	IN	_	_	_	_	_
22	average	_	_	JJ	_	_	_	_	_
23	now	_	_	RB	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	it	_	_	PRP	_	_	_	_	_
27	has	_	_	VBZ	_	_	_	_	_
28	become	_	_	VBN	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	public	_	_	JJ	_	_	_	_	_
31	health	_	_	NN	_	_	_	_	_
32	priority	_	_	NN	_	_	_	_	_
33	issue	_	_	NN	_	_	_	_	_
34	around	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	World	_	_	NNP	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	case	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	adults	_	_	NNS	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	children	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	treatment	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	both	_	_	DT	_	_	_	_	_
6	conditions	_	_	NNS	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	increasing	_	_	VBG	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	undertreatment	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	still	_	_	RB	_	_	_	_	_
13	prevalent	_	_	JJ	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	treatment	_	_	NN	_	_	_	_	_
16	effectiveness	_	_	NN	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	modest	_	_	JJ	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	pathway	_	_	NN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	mental	_	_	JJ	_	_	_	_	_
7	disorders	_	_	NNS	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	complex	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	interactive	_	_	JJ	_	_	_	_	_
13	process	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	over-reliance	_	_	NN	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	individual	_	_	JJ	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	at	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	expense	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	broader	_	_	JJR	_	_	_	_	_
25	“	_	_	``	_	_	_	_	_
26	structural	_	_	JJ	_	_	_	_	_
27	prevention	_	_	NN	_	_	_	_	_
28	”	_	_	''	_	_	_	_	_
29	approaches	_	_	NNS	_	_	_	_	_
30	has	_	_	VBZ	_	_	_	_	_
31	further	_	_	RBR	_	_	_	_	_
32	hindered	_	_	VBN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	successful	_	_	JJ	_	_	_	_	_
35	reduction	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	disease	_	_	NN	_	_	_	_	_
38	prevalence	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	unfortunate	_	_	JJ	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	WHO	_	_	NNP	_	_	_	_	_
7	evidence	_	_	NN	_	_	_	_	_
8	review	_	_	NN	_	_	_	_	_
9	on	_	_	IN	_	_	_	_	_
10	mental	_	_	JJ	_	_	_	_	_
11	health	_	_	NN	_	_	_	_	_
12	was	_	_	VBD	_	_	_	_	_
13	hampered	_	_	VBN	_	_	_	_	_
14	mainly	_	_	RB	_	_	_	_	_
15	by	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	broad	_	_	JJ	_	_	_	_	_
18	outcome	_	_	NN	_	_	_	_	_
19	selection	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	which	_	_	WDT	_	_	_	_	_
22	embraced	_	_	VBD	_	_	_	_	_
23	different	_	_	JJ	_	_	_	_	_
24	levels	_	_	NNS	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	severity	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	from	_	_	IN	_	_	_	_	_
29	health-related	_	_	JJ	_	_	_	_	_
30	quality	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	life	_	_	NN	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	clinical	_	_	JJ	_	_	_	_	_
35	outcomes	_	_	NNS	_	_	_	_	_
36	like	_	_	IN	_	_	_	_	_
37	depression	_	_	NN	_	_	_	_	_
38	or	_	_	CC	_	_	_	_	_
39	anxiety	_	_	NN	_	_	_	_	_
40	disorders	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	small	_	_	JJ	_	_	_	_	_
3	number	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	sub-section	_	_	NN	_	_	_	_	_
9	outcomes	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	diverse	_	_	JJ	_	_	_	_	_
13	measurement	_	_	NN	_	_	_	_	_
14	instruments	_	_	NNS	_	_	_	_	_
15	used	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	available	_	_	JJ	_	_	_	_	_
19	studies	_	_	NNS	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	symptom	_	_	NN	_	_	_	_	_
22	questionnaires	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	clinical	_	_	JJ	_	_	_	_	_
25	diagnoses	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	psychotropic	_	_	JJ	_	_	_	_	_
28	medication	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	prevented	_	_	VBD	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	authors	_	_	NNS	_	_	_	_	_
33	from	_	_	IN	_	_	_	_	_
34	conducting	_	_	VBG	_	_	_	_	_
35	full	_	_	JJ	_	_	_	_	_
36	meta-analyses	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Clark	_	_	NNP	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	Paunovic	_	_	NNP	_	_	_	_	_
4	concluded	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	there	_	_	EX	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	too	_	_	RB	_	_	_	_	_
9	few	_	_	JJ	_	_	_	_	_
10	studies	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	clinically	_	_	RB	_	_	_	_	_
13	significant	_	_	JJ	_	_	_	_	_
14	mental	_	_	JJ	_	_	_	_	_
15	health	_	_	NN	_	_	_	_	_
16	outcomes	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	studies	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	large	_	_	JJ	_	_	_	_	_
22	samples	_	_	NNS	_	_	_	_	_
23	were	_	_	VBD	_	_	_	_	_
24	needed	_	_	VBN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	quantitative	_	_	JJ	_	_	_	_	_
4	evidence	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	necessary	_	_	JJ	_	_	_	_	_
8	requirement	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	burden	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	disease	_	_	NN	_	_	_	_	_
13	estimation	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	setting	_	_	VBG	_	_	_	_	_
16	exposure	_	_	NN	_	_	_	_	_
17	guidelines	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	meantime	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	mental	_	_	JJ	_	_	_	_	_
7	health	_	_	NN	_	_	_	_	_
8	review	_	_	NN	_	_	_	_	_
9	included	_	_	VBD	_	_	_	_	_
10	papers	_	_	NNS	_	_	_	_	_
11	up	_	_	IN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	October	_	_	NNP	_	_	_	_	_
14	2015	_	_	CD	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	sufficient	_	_	JJ	_	_	_	_	_
19	number	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	new	_	_	JJ	_	_	_	_	_
22	studies	_	_	NNS	_	_	_	_	_
23	on	_	_	IN	_	_	_	_	_
24	more	_	_	RBR	_	_	_	_	_
25	severe	_	_	JJ	_	_	_	_	_
26	mental	_	_	JJ	_	_	_	_	_
27	health	_	_	NN	_	_	_	_	_
28	outcomes	_	_	NNS	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	such	_	_	JJ	_	_	_	_	_
31	as	_	_	IN	_	_	_	_	_
32	depression	_	_	NN	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	other	_	_	JJ	_	_	_	_	_
35	mental	_	_	JJ	_	_	_	_	_
36	health	_	_	NN	_	_	_	_	_
37	disorders	_	_	NNS	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	were	_	_	VBD	_	_	_	_	_
40	published	_	_	VBN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	few	_	_	JJ	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	were	_	_	VBD	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	longitudinal	_	_	JJ	_	_	_	_	_
7	design	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	improved	_	_	VBD	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	quality	_	_	NN	_	_	_	_	_
12	aspect	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	evidence	_	_	NN	_	_	_	_	_
16	base	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	that	_	_	DT	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	mind	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	aimed	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	supplement	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	WHO	_	_	NNP	_	_	_	_	_
12	review	_	_	NN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	providing	_	_	VBG	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	formal	_	_	JJ	_	_	_	_	_
17	meta-analysis	_	_	NN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	these	_	_	DT	_	_	_	_	_
20	additional	_	_	JJ	_	_	_	_	_
21	studies	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	By	_	_	IN	_	_	_	_	_
2	restricting	_	_	VBG	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	more	_	_	RBR	_	_	_	_	_
5	confined	_	_	VBN	_	_	_	_	_
6	clinical	_	_	JJ	_	_	_	_	_
7	outcomes	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	depression	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	anxiety	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	exposure	_	_	NN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	residential	_	_	JJ	_	_	_	_	_
20	road	_	_	NN	_	_	_	_	_
21	traffic	_	_	NN	_	_	_	_	_
22	noise	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	most	_	_	RBS	_	_	_	_	_
27	prevalent	_	_	JJ	_	_	_	_	_
28	type	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	traffic	_	_	NN	_	_	_	_	_
31	noise	_	_	NN	_	_	_	_	_
32	exposure	_	_	NN	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	too	_	_	RB	_	_	_	_	_
35	many	_	_	JJ	_	_	_	_	_
36	analysis	_	_	NN	_	_	_	_	_
37	subsets	_	_	NNS	_	_	_	_	_
38	can	_	_	MD	_	_	_	_	_
39	be	_	_	VB	_	_	_	_	_
40	avoided	_	_	VBN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	updated	_	_	JJ	_	_	_	_	_
3	meta-analysis	_	_	NN	_	_	_	_	_
4	should	_	_	MD	_	_	_	_	_
5	add	_	_	VB	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	growing	_	_	VBG	_	_	_	_	_
9	collection	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	up-to-date	_	_	JJ	_	_	_	_	_
12	systematic	_	_	JJ	_	_	_	_	_
13	reviews	_	_	NNS	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	health	_	_	NN	_	_	_	_	_
16	effects	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	traffic	_	_	NN	_	_	_	_	_
19	noise	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	e.	_	_	FW	_	_	_	_	_
22	g.	_	_	FW	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	birth	_	_	NN	_	_	_	_	_
25	outcomes	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	cardiovascular	_	_	JJ	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	metabolic	_	_	JJ	_	_	_	_	_
30	disease	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	behavioral/emotional	_	_	JJ	_	_	_	_	_
34	disorders	_	_	NNS	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	youth	_	_	NN	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_

